MINNEAPOLIS, Jan. 27, 2014 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ: UPI), a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions, today announced that it has appointed Dr.
Suranjan Roychowdhury as Vice
President of Research & Development and Clinical Affairs. This
newly created position within the Uroplasty organization was
established to provide focus, oversight and guidance to the
Company's product pipeline and clinical trials. Dr.
Roychowdhury joins Uroplasty with more than 20 years of functional
leadership experience and success in the development and
commercialization of implantable and disposable medical
devices.
"This new position adds an important element to our strategic
direction and product development capabilities. Suranjan's
highly relevant background and depth of experience will enable him
to immediately add value and provide direction to our R&D
initiatives, as well as lead our clinical programs," said
Rob Kill, President & CEO.
Dr. Roychowdhury served for more than eight years in advancing
executive roles with American Medical Systems, including leadership
of R&D as well as the Clinical, Regulatory, and Healthcare
Economics functions for the $230
million Men's Health division. Most recently, Dr.
Roychowdhury was with Vascular Solutions, a Minnesota-based cardiovascular medical device
company. He has also served in executive roles with Sulzer
Spine-Tech (now Zimmer Spine), Boston Scientific, and Schneider
USA (Pfizer).
Dr. Roychowdhury holds a B.Tech in Metallurgical Engineering
from the Indian Institute of Technology
at Varanasi, and M.S. and Ph.D. degrees in Materials Science &
Engineering from the University of Delaware. He is the author
of several publications on urology and cardiovascular topics.
In addition, he holds 20 issued US patents for medical
devices in Cardiology, Orthopedics, Urology and Drug Delivery.
About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects
approximately 41 million US adults. The symptoms include
urinary urgency, frequency and urge incontinence. The Urgent
PC Neuromodulation System is the only FDA cleared device that
delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom, is a
global medical device company that develops, manufactures and
markets innovative proprietary products for the treatment of
voiding dysfunctions. Our focus is the continued commercialization
of our Urgent® PC Neuromodulation System, the only commercially
available FDA-cleared system that delivers percutaneous tibial
nerve stimulation (PTNS) for the office-based treatment of
overactive bladder and associated symptoms of urgency, frequency
and urge incontinence. We also offer Macroplastique®, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and
CFO
952.426.6152
EVC Group
Leigh Salvo (Investors)/Janine McCargo (Business Media)
415.568.9349/646.688.0245
SOURCE Uroplasty, Inc.